Table 5

Comparison between factors and occurrence of drug use problems, drug interactions, and other problems
Factors Drug use problems (n = 50) Frequency (Percentage, %) Drug interactions (n = 63) Frequency (Percentage, %) Other problems (n = 97) Frequency (Percentage, %)
Yes No p-value Yes No p-value Yes No p-value
Elderly
Yes 17 (34.0) 68 (45.3) 0.215a 37 (58.7) 78 (56.9) 0.933a 57 (58.8) 58 (56.3) 0.836a
No 33 (66.0) 82 (54.7) 26 (41.3) 59 (43.1) 40 (41.2) 45 (43.7)
Polypharmacy
Yes 34 (68.0) 119 (79.3) 0.149a 58 (92.1) 95 (69.3) 0.001a* 74 (76.3) 79 (76.7) > 0.999a
No 16 (32.0) 31 (20.7) 5 (7.9) 42 (30.7) 23 (23.7) 24 (23.3)
Duration of hospital stay
≤ 1 week 37 (74.0) 106 (70.7) 0.786a 44 (69.8) 99 (72.3) 0.854a 65 (67.0) 78 (75.7) 0.227a
> 1 week 13 (26.0) 44 (29.3) 19 (30.2) 38 (27.7) 32 (33.0) 25 (24.3)
Microvascular complications
Yes 31 (62.0) 93 (62.0) > 0.999a 41 (65.1) 83 (60.6) 0.652a 65 (67.0) 59 (57.3) 0.204a
No 19 (38.0) 57 (38.0) 22 (34.9) 54 (39.4) 32 (33.0) 44 (42.7)
Cardiovascular disease
Yes 27 (54.0) 94 (62.7) 0.358a 53 (84.1) 68 (49.6) < 0.001a* 63 (64.9) 58 (56.3) 0.270a
No 23 (46.0) 56 (37.3) 10 (15.9) 69 (50.4) 34 (35.1) 45 (43.7)
Renal impairment
Yes 22 (44.0) 78 (52.0) 0.414a 33 (52.4) 67 (48.9) 0.761a 49 (50.5) 51 (49.5) > 0.999a
No 28 (56.0) 72 (48.0) 30 (47.6) 70 (51.1) 48 (49.5) 52 (50.5)
Liver impairement
Yes 4 (8.0) 7 (4.7) 0.472b 0 (0) 11 (8.0) 0.018b* 5 (5.2) 5 (5.8) > 0.999a
No 46 (92.0) 143 (95.3) 63 (100) 126 (92.0) 92 (94.8) 97 (94.2)
Hyperlipidemia
Yes 17 (34.0) 68 (45.3) 37 (58.7) 78 (56.9) 57 (58.8) 58 (56.3) 0.836a
No 33 (66.0) 82 (54.7) 0.215a 26 (41.3) 59 (43.1) 0.933a 40 (41.2) 45 (43.7)

a Computed using Continuity Correction; b Computed using Fisher’s Exact Test; * Statistically significant (p < 0.05).

Zaman Huri and Fun Wee

Zaman Huri and Fun Wee BMC Endocrine Disorders 2013 13:2   doi:10.1186/1472-6823-13-2

Open Data